Raltegravir
- Generic Name
- Raltegravir
- Brand Names
- Isentress
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN6O5
- CAS Number
- 518048-05-0
- Unique Ingredient Identifier
- 22VKV8053U
- Background
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
- Indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Post-exposure prophylaxis for occupational exposure to HIV therapy
RAL-eve Study: Raltegravir Substitution Study
- Conditions
- HIV Infections
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 14
- Registration Number
- NCT00523237
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Integrase Inhibitor (MK-0518) Viral Decay
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Canadian Immunodeficiency Research Collaborative
- Target Recruit Count
- 24
- Registration Number
- NCT00520897
- Locations
- 🇨🇦
Maple Leaf Medical Clinic, Toronto, Ontario, Canada
DDI HV (ATV - Merck)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00518297
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 53
- Registration Number
- NCT00515827
- Locations
- 🇺🇸
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States
🇺🇸Pitt CRS, Pittsburgh, Pennsylvania, United States
🇺🇸MetroHealth CRS, Cleveland, Ohio, United States
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 153
- Registration Number
- NCT00485264
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States
🇺🇸Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States
🇺🇸Usc La Nichd Crs, Alhambra, California, United States
Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses
- Conditions
- HIV Infections
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Target Recruit Count
- 103
- Registration Number
- NCT00460382
- Locations
- 🇫🇷
Hôpital Gustave Dron, Service Maladies Infectieuses, Tourcoing, France
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)
- Conditions
- HIV Infection
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 355
- Registration Number
- NCT00443729
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
- Conditions
- HIV Infections
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00377065
A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)
- First Posted Date
- 2006-08-30
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 566
- Registration Number
- NCT00369941
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 351
- Registration Number
- NCT00293254
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.